Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Ery... (esults in hyporesponsiveness ortolerance...)

Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus

Date:1/15/2008

esults in hyporesponsiveness, or tolerance, to antigens. In a preclinical study in a primate model, administration of TRX1 during the development of a primary immune response to a foreign protein, or antigen, resulted in longstanding and specific tolerance to that antigen. This type of suppression of the immune system may have therapeutic benefit in treating autoimmune diseases that occur when the human immune system mistakenly identifies the components of the human body as foreign.

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of patients with immune- mediated diseases. In addition to the development of TRX1, Tolerx is currently developing otelixizumab, an anti-CD3 MAb, in type 1 diabetes with its collaboration partner, GlaxoSmithKline. Tolerx is also engaged in preclinical development of new MAb product candidates that engage the body's immune system and further promote and enhance immune responses. This type of therapy is being researched for the treatment of cancer and chronic viral diseases.

Safe Harbor Statement

This press release contains certain statements that are preceded by, followed by, or that include the words "if," "will receive," "is expected to," "may have" or similar expressions or the negation thereof. Such statements, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements regarding Genentech's activities with respect to further development of TRX1, the potential value of payments that may be received by Tolerx pursuant to the agreement with Genentech, and the anticipated progress and development of TRX1 are all forward-looking statements. Such forward- looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, perf
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
2. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
3. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
4. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
5. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
6. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
7. Medarex to Receive Milestone Payment from Amgen
8. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
9. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
10. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
11. FASgen Announces Significant Milestone in Its Cancer Drug Development Program

Post Your Comments:

(Date:6/17/2013)... 17, 2013 Vanda Pharmaceuticals Inc. (Vanda) ... today at ENDO 2013, the Endocrine Society,s 95 ... entrain (synchronize) both melatonin and cortisol rhythms. This ... master body clock and address the circadian desynchrony ... SET (Safety and Efficacy of Tasimelteon) and RESET ...

(Date:6/17/2013)... , June 17, 2013 DNAtrix Inc., experts ... will present clinical data on the company,s lead product, ... Quebec City, Canada on June ... DNAtrix,s CEO and a leader in the field of ... study entitled A PHASE I TRIAL OF A CONDITIONALLY ...

(Date:6/17/2013)... 2013 BioMed Realty Trust, Inc. (NYSE: ... declared a second quarter 2013 dividend of $0.235 per share ... dividend of $0.94 per common share. The ... stockholders of record at the close of business on June ... BioMed Realty delivers optimal real estate solutions for biotechnology ...

Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2 Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3 Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4 DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2 BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2 BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3

[0] Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder [0] DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus [0] BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend

... Recent Highlights Strategic plan ... Term loan repaid Revolving line of credit renewed ... announced Cogdell Spencer Inc. (the "Company" or ... partner, is a REIT focused on planning, owning, developing, constructing, ...

... March 3, 2011 Dynatronics Corporation (Nasdaq: ... FirstChoice Cooperative, a group purchasing organization (GPO) headquartered in ... 20,000 members nationwide. The three-year agreement with FirstChoice is ... the third GPO contract signed in the past two ...

Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan Dynatronics Signs Third GPO Contract in Two Months

(Date:6/19/2013)... 2013 Faith4Kidz is starting a new fundraising ... Faith4Kidz would like help showing support for kids to learn ... more positive. Check out the website, http://www.gracenfaith.com to ... is red, white and blue stars as a symbol of ... history as well as the stars we should encourage our ...

(Date:6/18/2013)... (PRWEB) June 19, 2013 Consumer injury ... two other law firms have launched a new website ... caused by dialysis. The website is http://www.DialysisLawsuitAttorneys.com . ... time to begin offering legal services to people who ... GranuFlo and NaturaLyte, or who may have suffered injuries ...

(Date:6/18/2013)... As a sponsor of the 2013 Fourth of July ... Lake Meridian Chiropractic want you to get out and celebrate! ... event and are excited to be involved. “My husband and I ... loved going to the Kent Splash event. It's a tradition that ... to financially support this fun day.” , The 2013 ...

(Date:6/18/2013)... (PRWEB) June 19, 2013 "What if ... a day could boost your health and well-being? Well, ... founder of Sublime Beauty®. "It is called Skin ... centuries but became a lost art. Now, people are ... about Skin Brushing, and so do certain health conscious ...

(Date:6/18/2013)... New York, New York (PRWEB) June 19, 2013 ... dedicated to protecting the rights of victims injured by ... on behalf of an Arizona woman who alleges that ... The suit was filed on May 30th in the ... Virginia (Civil Action No. 2:13-cv-12677) in the multidistrict litigation ...

Breaking Medicine News(10 mins):Health News:Faith4Kidz Introduces Patriotic Hats to Benefit the "Grace in Faith Equals Peace" Mission 2 Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 2 Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 3 Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 4 Health News:Lake Meridian Chiropractic of Kent, WA to Sponsor the Fireworks Finale at 15th Annual Fourth of July Splash 2 Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2 Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 2 Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 3 Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 4

[0] Faith4Kidz Introduces Patriotic Hats to Benefit the "Grace in Faith Equals Peace" Mission [0] Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama [0] Lake Meridian Chiropractic of Kent, WA to Sponsor the Fireworks Finale at 15th Annual Fourth of July Splash [0] The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty®[0] Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman

... , FRIDAY, March 25 (HealthDay News) -- A small army ... of sick and dying animals from a rural North Carolina ... More than 400 animals -- 17 species in all, ... had been living in squalor with a middle-aged couple claiming ...

... FRIDAY, March 25 (HealthDay News) -- People looking for a ... joints sometimes turn to biking. Rather than a 30-minute jog ... hours on the bike, with little or no joint strain. ... physical activity raise a new problem: How to keep the ...

... Aurora, Colo. (March 24, 2011)A research team at the University ... be used to diagnose colon cancer earlier. It is possible ... the cancer. Colon cancer is the third most common cancer ... it, according to the American Cancer Society. This enzyme biomarker ...

... The US Food and Drug Administration announced today that ... the treatment of patients with metastatic melanoma. It is the ... with advanced melanoma. Ipilimumab uses a novel approach known ... attack cancer. The therapy, originally known as anti-CTLA-4, was developed ...

... Research Chair Peter Shizgal who investigates the roots ... recognized by his peers with the prestigious Prix Adrien ... Psychology and a member of the Centre for Studies ... qubcoise pour la recherche en psychologie (Quebec Society for ...

... , FRIDAY, March 25 (HealthDay News) -- A poor diet ... postmenopausal women, a new study has found. Researchers analyzed ... found that deficiencies in more than a single nutrient were ... Risk increased 44 percent with deficiencies in three nutrients. ...

Cached Medicine News:Health News:Animal 'Hoarding' Often Tied to Mental Illness 2 Health News:Animal 'Hoarding' Often Tied to Mental Illness 3 Health News:Animal 'Hoarding' Often Tied to Mental Illness 4 Health News:Cyclists Urged to Prep Their Bodies for the Long Haul 2 Health News:Cyclists Urged to Prep Their Bodies for the Long Haul 3 Health News:University of Colorado team identifies new colon cancer marker 2 Health News:Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma 2 Health News:Peter Shizgal distinguished by his peers 2 Health News:Poor Eating Habits May Lead to Anemia in Older Women 2

Animal 'Hoarding' Often Tied to Mental Illness Cyclists Urged to Prep Their Bodies for the Long Haul University of Colorado team identifies new colon cancer marker Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma Peter Shizgal distinguished by his peers Poor Eating Habits May Lead to Anemia in Older Women

The Carl Zeiss Head-worn Loupes L and LC are the ideal solution if a low magnification suffices for your work and you want to keep your hands free to perform the task at hand....

... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...

... delivers higher magnification for advanced surgical procedures. ... even at the highest magnification. 3.5x, 4.5x ... precise color rendition is ideal for surgical ... coating produce a superior image. The compact ...

... objective and high power negative lens delivering ... true benefit of this system is ease ... is made possible due to a superior ... bar and individual interpupillary adjustment provides stability ...

Medicine Products:

Head-worn Loupes L XL Advantage 5.5x @ 42cm working distance XL Advantage 3.5x @ 46cm working distance SuperVu 2.5x Galilean system